Fidelity Investments
ABUS icon

Fidelity Investments’s Arbutus Biopharma ABUS Stock Holding History

Fidelity Investments’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$653K Buy
145,126
+8,570
+6% +$37.5K ﹤0.01% 3016
2025
Q4 		$657K Buy
136,556
+47,092
+53% +$212K ﹤0.01% 2983
2025
Q3 		$406K Buy
89,464
+8,723
+11% +$32K ﹤0.01% 3108
2025
Q2 		$249K Buy
80,741
+2,732
+4% +$9.07K ﹤0.01% 3228
2025
Q1 		$272K Buy
78,009
+101
+0.1% +$337 ﹤0.01% 3132
2024
Q4 		$255K Sell
77,908
-5,372
-6% -$19.8K ﹤0.01% 3173
2024
Q3 		$321K Sell
83,280
-17,538
-17% -$67.3K ﹤0.01% 3027
2024
Q2 		$312K Sell
100,818
-65,024
-39% -$195K ﹤0.01% 2888
2024
Q1 		$428K Buy
165,842
+498
+0.3% +$1.29K ﹤0.01% 2771
2023
Q4 		$413K Sell
165,344
-10,795
-6% -$21.1K ﹤0.01% 2734
2023
Q3 		$358K Sell
176,139
-8,766
-5% -$18.4K ﹤0.01% 2720
2023
Q2 		$425K Sell
184,905
-1,812
-1% -$4.72K ﹤0.01% 2708
2023
Q1 		$566K Buy
186,717
+1,509
+0.8% +$4.26K ﹤0.01% 2652
2022
Q4 		$432K Sell
185,208
-1,568
-0.8% -$3.75K ﹤0.01% 2761
2022
Q3 		$357K Buy
186,776
+23,469
+14% +$55.3K ﹤0.01% 2883
2022
Q2 		$443K Sell
163,307
-823
-0.5% -$2.11K ﹤0.01% 2885
2022
Q1 		$489K Buy
+164,130
New +$502K ﹤0.01% 2994
2021
Q3 		– Sell
-1
Closed – – 4258
2021
Q2 		$0 Sell
1
-299
-100% -$926 ﹤0.01% 4166
2021
Q1 		$1K Buy
+300
New +$1.16K ﹤0.01% 3787
2017
Q4 		– Sell
-19,200
Closed -$119K – 2647
2017
Q3 		$119K Hold
19,200
– – ﹤0.01% 2577
2017
Q2 		$69K Hold
19,200
– – ﹤0.01% 2605
2017
Q1 		$62K Hold
19,200
– – ﹤0.01% 2636
2016
Q4 		$47K Hold
19,200
– – ﹤0.01% 2640
2016
Q3 		$66K Hold
19,200
– – ﹤0.01% 2640
2016
Q2 		$67K Hold
19,200
– – ﹤0.01% 2637
2016
Q1 		$79K Hold
19,200
– – ﹤0.01% 2646
2015
Q4 		$85K Buy
19,200
+7,600
+66% +$41.7K ﹤0.01% 2712
2015
Q3 		$71K Buy
+11,600
New +$103K ﹤0.01% 2703
2015
Q2 		– Sell
-11,600
Closed -$203K – 2719
2015
Q1 		$203K Buy
+11,600
New +$238K ﹤0.01% 2718

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Fidelity Investments's ABUS Position: Q1 2026 in Review

Fidelity Investments increased its Arbutus Biopharma (ABUS) stake by 6.3% in Q1 2026, buying an estimated $37.5K and bringing the position to 145,126 shares worth $653K. The position accounts for ﹤0.01% of the portfolio, ranked #3016.

Fidelity Investments first reported a position in ABUS in Q1 2015 and has held it in 29 quarters since. The position peaked at $657K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Fidelity Investments held 145,126 shares of Arbutus Biopharma worth $653K as of Q1 2026.
  • Fidelity Investments bought 8,570 Arbutus Biopharma shares in Q1 2026, an estimated $37.5K.
  • Arbutus Biopharma made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #3016 holding.
  • Fidelity Investments first reported a position in Arbutus Biopharma in Q1 2015 and has held it in 29 quarters since.
  • Fidelity Investments's Arbutus Biopharma position peaked at $657K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.